Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes

• Published in: Diabetes research and clinical practice Vol. 162; p. 108131
• Main Authors: Siegmund, Thorsten, Ampudia-Blasco, Francisco Javier, Schnell, Oliver
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.04.2020
• Subjects: Diabetes; Glycaemic variability; SGLT-2 inhibitor; Type 1 diabetes; T1DM; T2DM; ACE; isCGM; TaR; TbR; SGLT-2 inhibitor; CGM; Glycaemic variability; SGLT-2i; DEPICT; CV; Type 1 diabetes; EMA; Diabetes; DKA; rtCGM; TiR; HbA1c; BMI
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2020.108131

•SGLT-2is may improve glycaemic control reducing variability without increasing body weight.•Treatment of T1DM with SGLT-2is was not associated with major hypoglycaemia (<54 mg/dl).•Patients should be selected carefully and must be educated on potential side effects.•Especially occurrence of ketosis and/or diabetic ketoacidosis must be monitored. Type 1 diabetes mellitus (T1DM) prevalence is increasing and despite all available modern treatment options, an overall small but noticeable increase of mean HbA1c was recently observed in various registries. Authorized adjunctive pharmacological treatment options to insulin therapy are still scarce for T1DM. In February 2019, the European Medicines Agency (EMA) approved dapagliflozin as first in class sodium/glucose co-transporter 2 inhibitor (SGLT-2i) adjunctive therapy to insulin in patients with T1DM, which is currently still not approved by the FDA in the United States. SGLT-2is have shown significant improvement in HbA1c, reducing body weight and increasing time-in-range by reducing glycaemic variability, as well as reductions in total daily insulin dose in the trials in persons with T1DM. The cases presented here translate some of the observations gained from clinical trials into a real-world environment. They demonstrate that even highly practised and educated patients can benefit from the addition of a SGLT-2i as adjunctive treatment to insulin in T1DM. In summary, these cases demonstrate that a variety of patients with T1DM in a real-world setting may benefit from SGLT-2i treatment, as they have the potential to improve HbA1c, excess of body weight and increasing TiR among other things.